Astrazeneca Pharma India, 506820, ASTRAZEN Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

20,952.50
105.25
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

20,552.56
0.38%
25.43

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

11.78
16.10
19.61

EBITDA CAGR (%)

10 Years
5 Years
3 Years

31.50
13.39
8.99

PAT CAGR (%)

10 Years
5 Years
3 Years

36.22
4.40
5.24

P:E (Median)

8 Years
5 Years
3 Years

108.59
106.91
109.36

P:BV (Average)

8 Years
5 Years
3 Years

21.07
20.55
23.70

EV:EBITDA (Average)

8 Years
5 Years
3 Years

63.45
63.62
66.02

Earnings Forecasts:

(Updated: 18-04-2026)

Description 2024 2025 2026 2027
Adj EPS 46.3
P/E Ratio 182.84
Revenue 1716.29
EBITDA 253.97
Net Income 115.74
ROA 8.92
P/B Ratio 27.47
ROE 15.62
FCFF 94.05
FCFF Yield 0.49
Net Debt -500.97
BVPS 308.14

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated

Description Dec 25 Dec 24 Var% Sep 25 Sep 24 Var% Jun 25 Jun 24 Var% Mar 25 Mar 24 Var%
Net Sales 611.57 440.29 38.90% 559.09 408.00 37.03% 526.31 387.52 35.81% 480.48 383.20 25.39%
Expenses 566.74 363.30 56.00% 483.91 355.46 36.14% 445.20 349.45 27.40% 394.11 333.81 18.06%
EBITDA 44.83 76.99 -41.77% 75.18 52.54 43.09% 81.11 38.07 113.05% 86.37 49.39 74.87%
EBIDTM 7.33% 17.49% 13.45% 12.88% 15.41% 9.82% 17.98% 12.89%
Other Income 5.13 7.98 -35.71% 6.17 8.15 -24.29% 11.24 8.35 34.61% 16.15 8.73 84.99%
Interest 1.06 0.33 221.21% 0.67 0.34 97.06% 0.72 0.11 554.55% 0.68 0.00 0
Depreciation 3.84 9.07 -57.66% 2.57 9.32 -72.42% 16.57 3.91 323.79% 17.69 3.76 370.48%
PBT 46.54 42.02 10.76% 72.82 51.03 42.70% 74.70 -15.16 - 78.47 54.35 44.38%
Tax 13.95 11.17 24.89% 18.60 12.60 47.62% 18.87 -3.37 - 20.22 14.88 35.89%
PAT 32.59 30.85 5.64% 54.22 38.43 41.09% 55.83 -11.79 - 58.25 39.48 47.54%
PATM 5.33% 7.01% 9.70% 9.42% 10.61% -3.04% 12.12% 10.30%
EPS 13.04 12.34 5.67% 21.69 15.37 41.12% 22.33 -4.72 - 23.30 15.79 47.56%

Description Dec 25 Dec 24 Var% Sep 25 Sep 24 Var% Jun 25 Jun 24 Var% Mar 25 Mar 24 Var%
Net Sales 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Expenses 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBITDA 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBIDTM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Other Income 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Interest 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Depreciation 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PBT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Tax 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PAT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PATM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0

Annual Results

Standalone Figures in Rs. Crores

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Net Sales 2,177.45 1,716.29 1,295.53 1,002.97 805.60 813.56 831.81 728.29 571.00 543.71 563.73 Net Sales Growth 34.49% 32.48% 29.17% 24.50% -0.98% -2.19% 14.21% 27.55% 5.02% -3.55% Cost Of Goods Sold 1,245.90 957.79 590.03 355.22 305.28 287.30 299.97 226.73 178.21 171.18 194.81 Gross Profit 931.55 758.50 705.50 647.75 500.32 526.26 531.84 501.56 392.79 372.53 368.93 GP Margin 42.78% 44.19% 54.46% 64.58% 62.11% 64.69% 63.94% 68.87% 68.79% 68.52% 65.44% Total Expenditure 1,889.96 1,462.32 1,111.08 837.85 719.42 678.09 711.11 656.99 524.71 506.77 547.31 Power & Fuel Cost - 5.30 4.87 5.54 8.10 7.37 7.72 8.27 8.30 7.68 7.43 % Of Sales - 0.31% 0.38% 0.55% 1.01% 0.91% 0.93% 1.14% 1.45% 1.41% 1.32% Employee Cost - 257.44 241.45 259.10 230.21 219.54 216.70 197.40 150.39 162.04 169.35 % Of Sales - 15.00% 18.64% 25.83% 28.58% 26.99% 26.05% 27.10% 26.34% 29.80% 30.04% Manufacturing Exp. - 48.57 89.46 76.04 57.12 49.32 40.81 49.58 50.67 36.40 25.82 % Of Sales - 2.83% 6.91% 7.58% 7.09% 6.06% 4.91% 6.81% 8.87% 6.69% 4.58% General & Admin Exp. - 75.41 66.30 56.66 40.04 40.69 65.54 74.09 46.49 55.04 59.10 % Of Sales - 4.39% 5.12% 5.65% 4.97% 5.00% 7.88% 10.17% 8.14% 10.12% 10.48% Selling & Distn. Exp. - 103.93 97.48 71.57 62.09 55.94 65.13 88.18 81.07 62.56 84.65 % Of Sales - 6.06% 7.52% 7.14% 7.71% 6.88% 7.83% 12.11% 14.20% 11.51% 15.02% Miscellaneous Exp. - 13.88 21.49 13.72 16.58 17.93 15.24 12.74 9.58 11.87 84.65 % Of Sales - 0.81% 1.66% 1.37% 2.06% 2.20% 1.83% 1.75% 1.68% 2.18% 1.09% EBITDA 287.49 253.97 184.45 165.12 86.18 135.47 120.70 71.30 46.29 36.94 16.42 EBITDA Margin 13.20% 14.80% 14.24% 16.46% 10.70% 16.65% 14.51% 9.79% 8.11% 6.79% 2.91% Other Income 38.69 40.63 34.80 26.10 14.76 12.84 12.99 16.29 12.25 14.39 6.77 Interest 3.13 1.46 1.20 0.63 0.95 1.09 1.14 0.00 0.00 0.00 0.00 Depreciation 40.67 39.99 14.94 16.26 16.95 20.13 18.58 14.92 14.74 15.83 17.43 PBT 272.53 253.15 203.11 174.33 83.04 127.09 113.97 72.67 43.80 35.50 5.76 Tax 71.64 40.62 58.03 34.81 21.44 33.79 41.76 18.22 17.89 15.45 0.50 Tax Rate 26.29% 25.98% 26.43% 25.96% 25.82% 26.59% 36.64% 25.07% 40.84% 43.52% 8.68% PAT 200.89 115.74 161.51 99.29 61.60 93.30 72.21 54.45 25.91 20.05 5.26 PAT before Minority Interest 200.89 115.74 161.51 99.29 61.60 93.30 72.21 54.45 25.91 20.05 5.26 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 9.23% 6.74% 12.47% 9.90% 7.65% 11.47% 8.68% 7.48% 4.54% 3.69% 0.93% PAT Growth 107.17% -28.34% 62.66% 61.19% -33.98% 29.21% 32.62% 110.15% 29.23% 281.18% EPS 80.36 46.30 64.60 39.72 24.64 37.32 28.88 21.78 10.36 8.02 2.10

Results Balance Sheet

Standalone Figures in Rs. Crores

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Shareholder's Funds 770.35 711.92 588.69 511.39 456.17 364.44 300.80 246.93 222.87 156.01 Share Capital 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 Total Reserves 758.20 703.63 581.12 504.44 449.58 357.85 293.70 239.85 216.22 151.01 Non-Current Liabilities 159.13 97.83 68.99 73.63 44.60 44.13 22.75 109.73 88.68 38.96 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 162.24 116.30 85.97 84.91 50.50 49.47 46.11 142.28 128.90 37.70 Current Liabilities 908.15 467.15 484.40 392.30 373.43 367.10 267.60 218.67 202.05 234.05 Trade Payables 456.30 196.51 227.88 190.44 178.37 209.72 168.20 127.20 87.66 94.63 Other Current Liabilities 129.53 110.53 111.95 94.23 82.58 71.06 54.38 39.41 69.84 121.08 Short Term Borrowings 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Short Term Provisions 322.32 160.11 144.57 107.63 112.48 86.32 45.02 52.06 44.55 18.33 Total Liabilities 1,837.63 1,276.90 1,142.08 977.32 874.20 775.67 591.15 575.33 513.60 429.02 Net Block 64.24 66.68 68.86 74.49 80.96 71.53 74.83 75.46 86.84 97.36 Gross Block 217.62 187.13 179.12 168.83 159.78 132.84 119.83 105.85 102.57 203.76 Accumulated Depreciation 153.38 120.45 110.26 94.34 78.82 61.31 45.00 30.39 15.73 106.40 Non Current Assets 290.13 234.16 206.14 212.00 185.51 193.49 177.81 242.69 250.34 161.95 Capital Work in Progress 0.00 0.27 1.33 2.20 4.02 24.24 6.90 3.57 4.81 6.31 Non Current Investment 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Loans & Adv. 222.24 167.21 135.95 135.31 100.52 97.71 95.83 163.39 158.27 57.68 Other Non Current Assets 3.65 0.00 0.00 0.00 0.01 0.01 0.25 0.27 0.42 0.61 Current Assets 1,547.50 1,042.74 935.94 765.32 688.69 582.18 413.34 332.64 263.26 267.07 Current Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 548.50 227.88 190.21 140.22 159.80 165.15 118.10 113.15 57.71 76.73 Sundry Debtors 184.88 153.13 107.52 85.89 85.19 83.21 79.75 54.63 43.00 83.14 Cash & Bank 536.70 505.84 500.48 448.46 352.35 252.52 173.30 125.92 115.58 76.83 Other Current Assets 277.42 13.23 13.56 12.64 91.35 81.30 42.19 38.94 46.97 30.37 Short Term Loans & Adv. 261.22 142.66 124.17 78.11 81.51 71.18 33.26 30.87 26.74 20.22 Net Current Assets 639.35 575.59 451.54 373.02 315.26 215.08 145.74 113.97 61.21 33.03 Total Assets 1,837.63 1,276.90 1,142.08 977.32 874.20 775.67 591.15 575.33 513.60 429.02

Cash Flow

Standalone Figures in Rs. Crores

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Cash From Operating Activity 65.36 27.87 58.29 100.80 104.78 87.42 54.98 8.79 38.10 56.99 PBT 156.36 219.54 134.10 83.04 127.09 113.97 72.67 43.80 35.50 5.76 Adjustment 76.41 -7.07 -4.80 9.66 14.20 9.75 7.62 3.39 14.61 12.11 Changes in Working Capital -103.22 -128.17 -30.19 32.89 -3.95 -2.66 9.81 -34.25 -0.24 42.09 Cash after chg. in Working capital 129.55 84.30 99.11 125.59 137.34 121.06 90.10 12.94 49.87 59.97 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -64.19 -56.43 -40.82 -24.79 -32.56 -33.64 -35.12 -4.15 -11.77 -2.98 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity 30.80 21.74 18.11 4.74 173.03 -170.80 4.28 -9.36 0.25 -3.61 Net Fixed Assets -30.22 -6.95 -9.42 -7.23 -6.72 -30.35 -17.31 -2.04 102.69 -6.42 Net Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Others 61.02 28.69 27.53 11.97 179.75 -140.45 21.59 -7.32 -102.44 2.81 Cash from Financing Activity -65.59 -44.38 -24.48 -9.46 -8.97 -6.36 0.00 0.00 0.00 -0.51 Net Cash Inflow / Outflow 30.57 5.23 51.92 96.08 268.84 -89.74 59.26 -0.57 38.35 52.87 Opening Cash & Equivalents 505.57 500.34 448.42 352.34 83.50 173.24 113.98 114.55 76.20 23.33 Closing Cash & Equivalent 536.14 505.57 500.34 448.42 352.34 83.50 173.24 113.98 114.55 76.20

Financial Ratios

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Book Value (Rs.) 305.28 283.45 234.45 203.78 181.83 145.14 119.48 97.94 88.49 62.41 ROA 7.43% 13.35% 9.37% 6.65% 11.31% 10.57% 9.34% 4.76% 4.25% 1.25% ROE 15.73% 24.95% 18.13% 12.78% 22.83% 21.83% 20.03% 11.12% 10.63% 3.43% ROCE 21.29% 33.94% 24.49% 17.36% 31.24% 34.61% 26.53% 18.65% 18.74% 3.76% Fixed Asset Turnover 8.51 7.11 5.79 4.93 5.58 6.58 6.45 5.49 3.58 2.88 Receivable days 35.81 36.53 35.03 38.57 37.62 35.75 33.67 31.15 41.96 40.32 Inventory Days 82.25 58.60 59.85 67.64 72.59 62.15 57.95 54.51 44.72 52.15 Payable days 124.39 131.27 214.92 220.48 246.52 99.66 91.40 73.21 75.53 75.14 Cash Conversion Cycle -6.33 -36.14 -120.04 -114.26 -136.32 -1.76 0.22 12.45 11.15 17.33 Total Debt/Equity 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Interest Cover 108.10 183.95 213.86 88.41 117.60 100.97 0.00 0.00 0.00 0.00

Top Investors:

nippon life india trustee ltd-a/c nippon india small cap fund(various schemes)

tejas bhalchandra trivedi

shivani tejas trivedi

bandhan - various schemes

icici prudential - various schemes

prashant jain

investor education and protection fund (iepf)

llp

Annual Reports:

News Update:

AstraZeneca Pharma gets nod to import, market Acalabrutinib tablets 100 mg
13th Apr 2026, 10:08 AM

The company has received permission from the Central Drugs Standard Control Organisation
Read More
AstraZeneca Pharma gets nod to import, market Durvalumab Solution
17th Mar 2026, 18:20 PM

Through this approval, Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy
Read More
AstraZeneca Pharma gets CDSCO nod to import Durvalumab Solution
10th Feb 2026, 12:23 PM

The receipt of this permission paves way for the marketing of Durvalumab Solution for Infusion 120 mg/2.4 mL and 500 mg/10 mL (Imfinzi) in India for the specified additional indication
Read More
AstraZeneca Pharma gets nod to import for sale, distribution of Durvalumab Solution
31st Jan 2026, 16:32 PM

The company has received permission from the Central Drugs Standard Control Organisation
Read More

Astrazeneca Pharma India Ltd.

Pharmaceuticals & Drugs - Domestic

BSE: 506820 | NSE: ASTRAZEN

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Standalone Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Top Investors:

Annual Reports:

News Update:

Astrazeneca Pharma India Ltd.

Pharmaceuticals & Drugs - Domestic

BSE: 506820 | NSE: ASTRAZEN

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Standalone Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Top Investors:

Annual Reports:

News Update: